-
The United States Patent and Trademark Office (USPTO) has recently begun electronic delivery of search results from U.S. patent applications to the European Patent Office (EPO) to assist U.S. applicants who later file in the EPO to comply with amended Rule 141(1) of the EPO's implementing regulations to the European Patent Convention (EPC). As a result, U.S. applicants subject to amended Rule 141(1) EPC will not need to separately file their U.S. search results with the EPO, thereby providing time and cost savings to these applicants.
-
CAMBRIDGE, Mass. & LONDON -- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, and Cancer Research Technology Limited ...
-
... Background. This case arose from a patent suit in which Abbott Laboratories and its subsidia... USPTO arguments made by Abbott to the European Patent Office (EPO) in a proceeding regarding the ...
-
The European Patent Office (EPO) and the Indian government reached an agreement that is intended to protect India's traditional knowledge from piracy. EPO patent examiners were granted access to India's Traditional Knowledge Digital Library, which contains translations of Indian manuscripts and medical textbooks about traditional medicine (Ayurveda, Unani, Siddha, and Yoga) into English, French, German, Japanese, and Spanish from Hindi, Sanskrit, Arabic, Persian, Urdu, and other languages. The agreement with the EPO is the first of many expected to be coordinated with other patent agencies.
-
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the Opposition Division of the European Patent Office (EPO) has rendered an oral de...
-
WASHINGTON, Jan. 5 /U.S. Newswire/ -- Bavarian Nordic, the Denmark-based biopharmaceutical company that has developed a new smallpox vaccine and submitted a proposal to supply it to the U.S. government, has received a new patent for its product from the European Patent Office (EPO), which gives the company the exclusive rights to produce and sell the smallpox vaccine in Europe.
Peter Wulff, president and chief executive officer of Bavarian Nordic (http://www.bavarian-nordic.com ), said in a statement that the European patent further protects both the company's smallpox vaccine product and the company's core technology and noted that this latest patent "belongs to the same patent family as the earlier- issued U.S. patents.
-
RECENT DEVELOPMENTS . PATENTS . The Supreme Court considers the validity of Huma... as a matter of policy follow established EPO jurisprudence. . Human Genome Sciences Inc v Eli L... revoke Human Genome Sciences Inc's (HGS) European Patent (UK) 0,939,804 (the "Neutrokine Patent"). T... proceedings in the European Patent Office (EPO). The EPO had revoked the European patent on ...
-
... John Maraganore, Ph.D., Chief Executive Officer of Alnylam. "In particular, our Phase II study wit...* Joined GSK in Donating IP to Patent Pool for Neglected Tropical Diseases. Alnylam will.... * Kreutzer-Limmer II Patent Upheld in European Opposition Proceedings. The European Patent Officee (EPO) upheld the "Kreutzer-Limmer II" '061 (EP1352061) ...
-
... Patent and Trademark Office (DKPTO), European. Patent Office (EPO), Korean Intellectual Property...
-
... High Court, Halliburton v Comptroller of Patents ([2011] EWHC 2508), relating to the high-profile a... in this area for filing at the European Patent Office (EPO) and/or the United Kingdom Inte...